DK3929207T3 - Peptid fttftvt til anvendelse i behandling af fibrose - Google Patents

Peptid fttftvt til anvendelse i behandling af fibrose Download PDF

Info

Publication number
DK3929207T3
DK3929207T3 DK21168926.0T DK21168926T DK3929207T3 DK 3929207 T3 DK3929207 T3 DK 3929207T3 DK 21168926 T DK21168926 T DK 21168926T DK 3929207 T3 DK3929207 T3 DK 3929207T3
Authority
DK
Denmark
Prior art keywords
fibrosis
treatment
fttftvt
peptide
peptide fttftvt
Prior art date
Application number
DK21168926.0T
Other languages
Danish (da)
English (en)
Inventor
Sreerama Shetty
Steven Idell
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Application granted granted Critical
Publication of DK3929207T3 publication Critical patent/DK3929207T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK21168926.0T 2013-03-15 2014-03-17 Peptid fttftvt til anvendelse i behandling af fibrose DK3929207T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361800117P 2013-03-15 2013-03-15
EP14762435.7A EP2970383B1 (en) 2013-03-15 2014-03-17 Method of treating fibrosis

Publications (1)

Publication Number Publication Date
DK3929207T3 true DK3929207T3 (da) 2024-10-21

Family

ID=51537978

Family Applications (2)

Application Number Title Priority Date Filing Date
DK21168926.0T DK3929207T3 (da) 2013-03-15 2014-03-17 Peptid fttftvt til anvendelse i behandling af fibrose
DK14762435.7T DK2970383T3 (da) 2013-03-15 2014-03-17 Fremgangsmåde til behandling af fibrose

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK14762435.7T DK2970383T3 (da) 2013-03-15 2014-03-17 Fremgangsmåde til behandling af fibrose

Country Status (11)

Country Link
US (8) US9630990B2 (enExample)
EP (3) EP4438044A3 (enExample)
JP (4) JP6603207B2 (enExample)
KR (3) KR102268883B1 (enExample)
CN (3) CN117679487A (enExample)
AU (3) AU2014233055B2 (enExample)
CA (1) CA2904870C (enExample)
DK (2) DK3929207T3 (enExample)
ES (2) ES2875853T3 (enExample)
PT (2) PT3929207T (enExample)
WO (1) WO2014145389A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3061808B1 (en) 2009-02-03 2020-08-12 Koninklijke Nederlandse Akademie van Wetenschappen Culture medium for epithelial stem cells and organoids comprising said stem cells
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
PT3929207T (pt) 2013-03-15 2024-10-21 Univ Texas Utilização do péptido fttftvt no tratamento de fibrose
EP3099380B1 (en) 2014-01-28 2021-08-11 Buck Institute for Research on Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
WO2015116735A1 (en) 2014-01-28 2015-08-06 Mayo Foundation For Medical Education And Research Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
US10597633B2 (en) 2014-05-16 2020-03-24 Koninklijke Nederlandse Akademie Van Wetenschappen Culture method for organoids
GB201421094D0 (en) 2014-11-27 2015-01-14 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium
GB201421092D0 (en) 2014-11-27 2015-01-14 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium
US20180050084A1 (en) * 2015-02-27 2018-02-22 Board Of Regents, The University Of Texas System Polypeptide therapeutics and uses thereof
GB201603569D0 (en) 2016-03-01 2016-04-13 Koninklijke Nederlandse Akademie Van Wetenschappen Improved differentiation method
WO2018190680A1 (ko) * 2017-04-13 2018-10-18 충남대학교산학협력단 세포내 결핵균 제어를 위한 뉴트린-3α 및 피53 발현 조절 조성물 또는 방법
KR102082285B1 (ko) * 2017-04-13 2020-02-28 충남대학교산학협력단 세포내 결핵균 제어를 위한 Nutlin-3α (뉴트린-3α) 및 p53 발현 조절 조성물 또는 방법
CN107987128B (zh) * 2017-11-17 2019-06-11 广东医科大学 一种功能多肽及其在制备防治肺纤维化药物中的应用
US12281180B2 (en) 2018-07-13 2025-04-22 New York University Peptoid-peptide macrocycles, pharmaceutical compositions and methods of using the same
EP3849581A4 (en) * 2018-09-10 2022-07-06 Board of Regents, The University of Texas System DRY POWDER FORMULATION OF CAVEOLIN-1 PEPTIDES AND METHODS OF USE THEREOF
EP3849580A4 (en) 2018-09-10 2022-06-15 Lung Therapeutics, Inc. Modified peptide fragments of cav-1 protein and the use thereof in the treatment of fibrosis
CN109010798A (zh) * 2018-09-17 2018-12-18 中山大学中山眼科中心 一种多肽的新用途
GB201819224D0 (en) 2018-11-26 2019-01-09 Koninklijke Nederlandse Akademie Van Wetenschappen Hepatocyte expansion methods
AU2020417604A1 (en) * 2019-12-31 2022-08-11 Xiamen Innovax Biotech Co., Ltd. Multimerization delivery system for intracellular delivery of molecule
WO2022182949A2 (en) 2021-02-25 2022-09-01 Lung Therapeutics, Inc. Biomarkers for the treatment of interstitial lung disease
WO2022217037A1 (en) 2021-04-09 2022-10-13 Board Of Regents, The University Of Texas System Compositions and methods for treatment of chronic lung diseases
CN119258210A (zh) * 2023-07-06 2025-01-07 厦门大学 新型疫苗递送体系
CN116789751B (zh) * 2023-08-22 2023-11-17 中国农业大学 预防和/或治疗纤维化疾病的多肽及其应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4021387A (en) 1975-11-19 1977-05-03 President And Fellows Of Harvard College Eosinophilotactic tetrapeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4816449A (en) 1984-08-09 1989-03-28 Immunetech Pharmaceuticals Immunotherapeutic anti-inflammatory peptide agents
US4613676A (en) * 1983-11-23 1986-09-23 Ciba-Geigy Corporation Substituted 5-amino-4-hydroxyvaleryl derivatives
ZA846192B (en) 1984-08-09 1986-03-26 Merck Patent Gmbh Immunotherapeutic polypeptide agents
US5728680A (en) 1987-12-30 1998-03-17 Cytoven J.V. Methods for normalizing numbers of lymphocytes
DK53291D0 (da) * 1991-03-25 1991-03-25 Carlbiotech Ltd As Smaa peptider og peptidrelaterede stoffer samt farmaceutiske praeparater indeholdende saadanne forbindelser
CA2150371C (en) * 1992-12-11 2002-09-17 Dov Borovsky Materials and methods for control of pests
US5559209A (en) * 1993-02-18 1996-09-24 The General Hospital Corporation Regulator regions of G proteins
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
US6017735A (en) 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
US20030113271A1 (en) 1997-01-29 2003-06-19 University Technology Corporation Formulations for pulmonary delivery
EP1076091A1 (en) 1999-08-09 2001-02-14 Universite Catholique De Louvain Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds
US20020077283A1 (en) 2000-09-08 2002-06-20 Sessa William C. Caveolin peptides and their use as therapeutics
EP1353676A4 (en) 2000-12-29 2006-05-31 Alteon Inc METHOD FOR THE TREATMENT OF FIBROUS OR OTHER INDICATIONS
GB0119852D0 (en) 2001-08-15 2001-10-10 Univ York Baculovirus
EP1458380B1 (en) 2001-12-18 2008-03-19 F.Hoffmann-La Roche Ag Cis-2,4,5- triphenyl-imidazolines and their use in the treatment of tumors
US7625865B2 (en) 2004-03-26 2009-12-01 Universita Degli Studi Di Parma Insulin highly respirable microparticles
US8101726B2 (en) * 2004-05-25 2012-01-24 Tactic Pharma, Llc Ligands binding the complex of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) that inhibit downstream uPAR interactions: identification and use in diagnosis or therapy
US7893278B2 (en) 2004-06-17 2011-02-22 Hoffman-La Roche Inc. CIS-imidazolines
TWI299993B (en) 2005-12-15 2008-08-21 Dev Center Biotechnology Aqueous inhalation pharmaceutical composition
US8058227B2 (en) * 2006-10-03 2011-11-15 Medical University Of South Carolina Method of treating fibrosis in a subject in need thereof comprising administering a composition comprising a CSD
US8487072B2 (en) * 2006-10-19 2013-07-16 Angiochem Inc. Compounds for stimulating P-glycoprotein function and uses thereof
EA201000785A1 (ru) 2007-12-13 2011-02-28 Глаксо Груп Лимитед Композиции для доставки в легкие
CN107162928B (zh) * 2007-12-21 2022-03-11 塞尔塔医疗有限公司 抗纤维化剂的卤代类似物
WO2009111625A2 (en) 2008-03-05 2009-09-11 Board Of Regents, The University Of Texas System Peptide inhibition of lung epithelial apoptosis and pulmonary fibrosis
SG193209A1 (en) 2008-09-10 2013-09-30 Genentech Inc Methods for inhibiting ocular angiogenesis
GB2466121B (en) 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
CN102753148B (zh) 2010-02-11 2018-01-26 埃博灵克斯股份有限公司 用于制备气雾剂的方法和组合物
EP2635686B1 (en) 2010-11-05 2018-03-28 The Regents of The University of California Neuronal specific targeting of caveolin expression to restore synaptic signaling and improve cognitive function in the neurodegenerative brain and motor function in spinal cord
WO2013184482A1 (en) 2012-06-04 2013-12-12 Yale University Method of treating and preventing ocular angiogenesis
KR20180092324A (ko) 2013-03-13 2018-08-20 포레스트 래보러토리즈 홀딩스 리미티드 미분화된 약제학적 조성물
PT3929207T (pt) 2013-03-15 2024-10-21 Univ Texas Utilização do péptido fttftvt no tratamento de fibrose
CA2928759A1 (en) 2013-11-04 2015-05-07 Board Of Regents, The University Of Texas System Compositions and methods for administration of an enzyme to a subject's airway
ES2743622T3 (es) 2013-11-26 2020-02-20 E & B Tech Llc Tratamiento de la enfermedad autoinmune y/o inflamatoria usando moduladores de la caveolina novedosos
US9908915B2 (en) 2013-11-26 2018-03-06 Yale University Cell-penetrating compositions and methods using same
EP3849580A4 (en) 2018-09-10 2022-06-15 Lung Therapeutics, Inc. Modified peptide fragments of cav-1 protein and the use thereof in the treatment of fibrosis
EP3849581A4 (en) 2018-09-10 2022-07-06 Board of Regents, The University of Texas System DRY POWDER FORMULATION OF CAVEOLIN-1 PEPTIDES AND METHODS OF USE THEREOF

Also Published As

Publication number Publication date
US9630990B2 (en) 2017-04-25
US20250304619A1 (en) 2025-10-02
EP4438044A2 (en) 2024-10-02
AU2020203192A1 (en) 2020-06-04
JP2021178856A (ja) 2021-11-18
CN110201144A (zh) 2019-09-06
EP2970383B1 (en) 2021-04-21
ES2993671T3 (en) 2025-01-03
JP2018158952A (ja) 2018-10-11
US20160272678A1 (en) 2016-09-22
US11161875B2 (en) 2021-11-02
CN117679487A (zh) 2024-03-12
EP3929207A1 (en) 2021-12-29
JP6975690B2 (ja) 2021-12-01
KR102588702B1 (ko) 2023-10-16
US20180086791A1 (en) 2018-03-29
US20200165298A1 (en) 2020-05-28
US11780879B2 (en) 2023-10-10
JP6603207B2 (ja) 2019-11-06
JP7378833B2 (ja) 2023-11-14
EP4438044A3 (en) 2024-12-04
HK1218924A1 (zh) 2017-03-17
CN110201144B (zh) 2024-01-02
ES2875853T3 (es) 2021-11-11
EP3929207B1 (en) 2024-07-17
BR112015023287A2 (pt) 2019-11-19
PT3929207T (pt) 2024-10-21
PT2970383T (pt) 2021-06-03
CN105263948A (zh) 2016-01-20
KR20150128731A (ko) 2015-11-18
DK2970383T3 (da) 2021-07-05
US20220098239A1 (en) 2022-03-31
US20230100467A1 (en) 2023-03-30
AU2014233055B2 (en) 2018-08-09
CA2904870A1 (en) 2014-09-18
KR102268883B1 (ko) 2021-06-28
AU2014233055A1 (en) 2015-10-01
US12173089B2 (en) 2024-12-24
CA2904870C (en) 2022-08-23
KR20230148263A (ko) 2023-10-24
AU2018205157A1 (en) 2018-08-02
EP2970383A4 (en) 2016-12-21
CN105263948B (zh) 2019-06-04
KR20210076190A (ko) 2021-06-23
WO2014145389A1 (en) 2014-09-18
JP2016522159A (ja) 2016-07-28
US10377796B2 (en) 2019-08-13
US20240059736A1 (en) 2024-02-22
US20170253632A1 (en) 2017-09-07
JP2023178440A (ja) 2023-12-14
EP2970383A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
DK3929207T3 (da) Peptid fttftvt til anvendelse i behandling af fibrose
PL3542798T3 (pl) Aceklidyna do zastosowania w leczeniu starczowzroczności
DK3033102T3 (da) Peptidkonjugerede partikler
HRP20181213T1 (hr) Peptidna smjesa
DK3197472T3 (da) Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri
IL245744A0 (en) Therapeutic peptides
DK3415525T3 (da) Amfipatisk peptid
PL2964250T3 (pl) Peptydy i kompozycje do leczenia uszkodzenia stawu
PL3004155T3 (pl) Związek peptydowy
LT2986722T (lt) Rekombinantiniai fenilalanino amonio liazės polipeptidai
SG11201506766PA (en) Therapeutic peptides
DK3058936T3 (da) Peptidsammensætning og anvendelser deraf
SG11201508469YA (en) Therapeutic peptides
DK3234107T3 (da) B-celler til in vivo-levering af terapeutiske midler
HUE049103T2 (hu) Antimikrobiális peptid
DK3590566T3 (da) Kropsbåret injektor
EP2812347A4 (en) PEPTIDE INDUCING AUTOPHAGIA
DK3044229T3 (da) Peptider til anvendelse i behandlingen af oral mucositis
DK3236960T3 (da) Fluralaner til anvendelse i behandling af demodicose
DK3094322T3 (da) Administration af tasimelteon i fastende tilstand
DK3226854T3 (da) Aminosyrebaseret sammensætning til genoprettelse af fibroelastin i hudens bindevæv
EP2976353A4 (en) Autophagy-inducing peptide analogs
LT3030259T (lt) Peptidai
IL240701B (en) Kntc2 peptides and vaccines containing the same
HUE040418T2 (hu) Antimikrobiális peptid és felhasználásai